Freedom of mobility for every person
Building on osseointegration and next-generation bionics, Integrum develops products and technologies that bring the person and the prosthesis closer together.
Integrum is a Swedish medical technology company with roots in the research that laid the foundation for osseointegration. The company develops products and technologies designed to create a more direct and functional connection between the human body and external prostheses.
At the center of Integrum's current commercial operations is the OPRA™ Implant System, a prosthetic system anchored directly in the bone, creating a stable connection between the body and the prosthesis and removing the need for a conventional socket. More than 1,000 patients worldwide have been treated with the OPRA™ Implant System. The system is certified under the EU Medical Device Regulation (MDR) and approved by the U.S. Food and Drug Administration (FDA). In the US, OPRA™ is the only FDA-approved bone-anchored implant system developed specifically for people who have undergone amputation.
In parallel, Integrum is developing next-generation bionic solutions, where e-OPRA and neural interfaces have the potential to enable advanced intuitive control and sensory feedback between humans and prosthetics in the future.
Integrum AB is listed on the Nasdaq First North Growth Market (INTEG B).
Key Figures
| 3 months | 12 months | ||
|---|---|---|---|
| Amounts in SEK thousand | 31 Jul 2026 | 31 Jul 2025 | 30 Apr 2026 |
| Net sales | 30 221 | 23 793 | 91 385 |
| Net sales growth (%) | 27.0 | 28.9 | 0.3 |
| Gross margin (%) * | 102.3 | 80.1 | 77.0 |
| EBITDA | 3 837 | -10 703 | -41 259 |
| Operating profit/loss | 1 309 | -12 429 | -53 157 |
| Profit/loss before tax | 1 213 | -12 540 | -53 699 |
| Equity/asset ratio (%) | 87.5 | 86.7 | 84.5 |
| Number of employees (FTE) at end of period | 33 | 36 | 32 |
| Equity per share, SEK | 6.5 | 7.9 | 6.4 |
| Share price on balance sheet date, SEK | 8.8 | 41.7 | 7.8 |
| Market value on balance sheet date, SEK million | 234.1 | 888.6 | 209.1 |
| Stage 1 surgeries (S1) US | 32 | 27 | 116 |
| Stage 1 surgeries (S1) EMEA | 16 | 14 | 59 |
| Stage 1 surgeries (S1) Total | 48 | 41 | 175 |
* Gross margin exceeded 100% in the quarter due to a SEK 6,2 million refund of previously paid U.S. customs duties recognized in cost of goods sold. Adjusted for this item, the gross margin was 82%.